Nexalis Therapeutics (ASX:NX1) Total Liabilities: A$2.38 Mil (As of Dec. 2025)


What is Nexalis Therapeutics Total Liabilities?

Nexalis Therapeutics ASX:NX1 Total Liabilities is A$2.38 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Nexalis Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was A$2.38 Mil.

Nexalis Therapeutics's quarterly Total Liabilities increased from Dec. 2024 (A$0.78 Mil) to Jun. 2025 (A$2.31 Mil) and increased from Jun. 2025 (A$2.31 Mil) to Dec. 2025 (A$2.38 Mil).

Nexalis Therapeutics's annual Total Liabilities declined from Dec. 2023 (A$0.91 Mil) to Dec. 2024 (A$0.78 Mil) but then increased from Dec. 2024 (A$0.78 Mil) to Dec. 2025 (A$2.38 Mil).

Nexalis Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nexalis Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalis Therapeutics Total Liabilities Chart

Nexalis Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.33 0.91 0.78 2.38

Nexalis Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.63 0.78 2.31 2.38

Nexalis Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nexalis Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.067+(0.315+-1.6566609195579E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.001+0)
=2.38

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1.208--1.175
=2.38

Nexalis Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.067+(0.315+-1.6566609195579E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.001+0)
=2.38

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1.208--1.175
=2.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$2.38 Mil mean?
Nexalis Therapeutics (ASX:NX1) has a Total Liabilities of A$2.38 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nexalis Therapeutics and its competitors.
Is Nexalis Therapeutics' Total Liabilities too high?
Nexalis Therapeutics' current Total Liabilities is A$2.38 Mil.
How does Nexalis Therapeutics' Total Liabilities compare to VRTX and REGN?
Nexalis Therapeutics' Total Liabilities of A$2.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current Total Liabilities is A$2.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current Total Liabilities of A$2.38 Mil. The current Total Liabilities is A$2.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current Total Liabilities is A$2.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.